{"id":2895,"date":"2021-03-30T23:35:49","date_gmt":"2021-03-30T23:35:49","guid":{"rendered":"\/\/smallcapscn.x5view.co\/?p=2895"},"modified":"2023-08-29T17:49:01","modified_gmt":"2023-08-29T17:49:01","slug":"invex-therapeutics-pre-ind-meeting-us-fda-presendin-trial-iih-sufferers","status":"publish","type":"post","link":"https:\/\/smallcapscn.x5view.co\/?p=2895","title":{"rendered":"Invex Therapeutics\u4e0e\u7f8e\u56fdFDA\u5c31Presendin&#x2122;\u5728IIH\u60a3\u8005\u4e2d\u7684\u4e34\u5e8a\u8bd5\u9a8c\u8fdb\u884c\u4e86pre-IND\u4f1a\u8c08"},"content":{"rendered":"<p><a href=\"http:\/\/smallcaps-production.test\/stocks\/?symbol=IXC&amp;lang=cn\">Invex Therapeutics (ASX: IXC)<\/a>\u5df2\u5411\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40(fda)\u63d0\u4ea4\u4e86\u4e00\u4efd\u7814\u7a76\u524d\u65b0\u836f\u7533\u8bf7\uff0c\u7528\u4e8eIII\u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u8bc4\u4f30\u5176\u836f\u7269Presendin\u7528\u4e8e\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b(IIH)\u60a3\u8005\u3002<\/p>\n<p>\u5728\u63d0\u4ea4\u7533\u8bf7\u7684\u540c\u65f6\uff0cInvex\u6b63\u5728\u5bfb\u6c42\u4e0eFDA\u53ec\u5f00pre-IND\/ B\u578b\u4f1a\u8bae\uff0c\u5728\u90a3\u91cc\u5b83\u5c06\u83b7\u5f97\u62df\u8bae\u8bd5\u9a8c\u7684\u534f\u8bae\u534f\u52a9\uff0c\u5305\u62ec\u8bd5\u9a8c\u7ec8\u70b9\u7684\u6307\u5bfc\uff0c\u5305\u62ec\u6bcf\u6708\u5934\u75db\u65e5\u548c\u9885\u5185\u538b\u3002<\/p>\n<p>\u6839\u636e\u8be5\u516c\u53f8\u7684\u8bf4\u6cd5\uff0c\u6bcf\u6708\u7684\u5934\u75db\u65e5\u548c\u9885\u5185\u538b\u4e0e\u53bb\u5e74\u5e74\u5e95\u5728Presendin\u5b64\u513f\u836f\u6307\u5b9a\u4e0b\u4eceEuropean Medicines Agency\u5f97\u5230\u7684\u6cbb\u7597\u65b9\u6848\u5efa\u8bae\u4e00\u81f4\u3002<\/p>\n<p>\u4f5c\u4e3aFDA\u4e4b\u524d\u8981\u6c42\u7684\u4e00\u90e8\u5206\uff0cInvex\u4e5f\u5411FDA\u63d0\u4ea4\u4e86\u4e00\u4efd\u5b8c\u6574\u7684\u7814\u7a76\u65b9\u6848\u548c\u7edf\u8ba1\u5206\u6790\u8ba1\u5212\u3002<\/p>\n<p>Invex\u8463\u4e8b\u957fJason Loveridge\u535a\u58eb\u8868\u793a\uff0cFDA\u7684\u7533\u8bf7\u5bf9\u8be5\u516c\u53f8\u6765\u8bf4\u662f\u4e00\u4e2a\u201c\u91cd\u8981\u7684\u91cc\u7a0b\u7891\u201d\u3002<\/p>\n<p>\u201d\u534f\u8bae\u7684\u7814\u7a76\u548c\u7edf\u8ba1\u5206\u6790\u8ba1\u5212\u7684\u5b8c\u6210\u5728\u5927\u7ea6\u4e09\u4e2a\u6708\u7684\u6700\u540e\u83b7\u5f97\u6b27\u6d32\u836f\u54c1\u5c40\u53cd\u9988\u8bc1\u660eInvex\u56e2\u961f\u7684\u627f\u8bfa,\u6211\u4eec\u7684\u4e13\u5bb6\u533b\u7597\/\u79d1\u5b66\u548c\u7ba1\u7406\u987e\u95ee\u548c\u7814\u7a76\u7edf\u8ba1\u5b66\u5bb6\u4e3aPresendin\u7279\u53d1\u6027\u9885\u5185\u9ad8\u8840\u538b\u53d1\u5c55\u9879\u76ee<\/p>\n<p>Loveridge\u535a\u58eb\u8865\u5145\u8bf4\uff0cFDA\u7684\u53cd\u9988\u5c06\u662f\u4e00\u4e2a\u201c\u91cd\u8981\u7684\u8003\u8651\u56e0\u7d20\u201d\uff0c\u56e0\u4e3aInvex\u6253\u7b97\u57289\u6708\u4efd\u7684\u5b63\u5ea6\u4f1a\u8bae\u6b63\u5f0f\u8bb0\u5f55\u4e4b\u540e\u63d0\u4ea4IND\u3002<\/p>\n<p>\u201c\u6211\u4eec\u5f88\u9ad8\u5174\u6709\u673a\u4f1a\u4e0eFDA\u5206\u4eab\u6211\u4eec\u7684\u8ba1\u5212\uff0c\u6211\u4eec\u63d0\u8bae\u7684\u4f1a\u8bae\u8981\u6c42\u83b7\u5f97\u6279\u51c6\u3002\u201d<\/p>\n<p>Loveridge\u535a\u58eb\u6307\u51fa\uff0c\u62df\u8bae\u7684III\u671f\u8bd5\u9a8c\u5bf9\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u60a3\u8005\u5f88\u91cd\u8981\uff0c\u4ed6\u4eec\u76ee\u524d\u4e0d\u80fd\u4f9d\u8d56\u4efb\u4f55\u5df2\u6279\u51c6\u7684\u6cbb\u7597\u65b9\u6cd5\u6765\u6709\u6548\u5730\u7ba1\u7406\u8fd9\u79cd\u75be\u75c5\uff0c\u5e76\u6539\u5584\u4ed6\u4eec\u7684\u751f\u6d3b\u8d28\u91cf\uff0c\u5982\u51cf\u5c11\u5934\u75db\u3002<\/p>\n<h2>\u7279\u53d1\u6027\u9885\u5185\u9ad8\u8840\u538b<\/h2>\n<p>\u6839\u636eInvex\u7684\u8bf4\u6cd5\uff0c\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u662f\u4e00\u79cd\u4ee5\u201c\u9885\u5185\u538b\u4e25\u91cd\u5347\u9ad8\u201d\u4e3a\u7279\u5f81\u7684\u81f4\u6b8b\u6027\u75be\u75c5\u3002\u8fd9\u4f1a\u5bfc\u81f4\u65e5\u5e38\u5934\u75db\u5e76\u538b\u8feb\u89c6\u795e\u7ecf\u3002<\/p>\n<p>\u53d1\u75c5\u5e74\u9f84\u901a\u5e38\u572820 &#8211; 30\u5c81\u4e4b\u95f4\uff0c\u591a\u89c1\u4e8e\u80a5\u80d6\u5973\u6027\u3002<\/p>\n<p>Invex\u6307\u51fa\uff0c\u8fd9\u79cd\u75be\u75c5\u662f\u4e00\u79cd\u5feb\u901f\u589e\u957f\u7684\u8ff9\u8c61\u2014\u2014\u5728\u8fc7\u53bb\u5341\u5e74\u4e2d\uff0c\u53d1\u75c5\u7387\u589e\u52a0\u4e86350%\u4ee5\u4e0a\u3002<\/p>\n<p>Presendin\u662fInvex\u516c\u53f8\u827e\u585e\u90a3\u80bd\u7684\u54c1\u724c\u540d\u79f0\uff0c\u66fe\u4e8e2005\u5e74\u548c2006\u5e74\u83b7\u5f97\u7f8e\u56fd\u548c\u6b27\u76df\u6279\u51c6\u7528\u4e8e\u6cbb\u75972\u578b\u7cd6\u5c3f\u75c5\u3002<\/p>\n<p>\u7814\u7a76\u8868\u660e\uff0c\u8fd9\u79cd\u836f\u7269\u6700\u7ec8\u53ef\u4ee5\u51cf\u5c11\u5927\u8111\u4e2d\u7684\u8111\u810a\u6db2\u3002\u7136\u800c\uff0c\u76ee\u524d\u7cd6\u5c3f\u75c5\u7684\u5242\u578b\u5e76\u6ca1\u6709\u88ab\u4f18\u5316\u7528\u4e8e\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u3002<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Invex Therapeutics (ASX: IXC)\u5df2\u5411\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40(fda)\u63d0\u4ea4\u4e86\u4e00\u4efd\u7814\u7a76\u524d\u65b0\u836f\u7533\u8bf7\uff0c\u7528\u4e8eIII\u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u8bc4\u4f30\u5176\u836f\u7269Presendin\u7528\u4e8e\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b(IIH)\u60a3\u8005\u3002 \u5728\u63d0\u4ea4\u7533\u8bf7\u7684\u540c\u65f6\uff0cInvex\u6b63\u5728\u5bfb\u6c42\u4e0eFDA\u53ec\u5f00pre-IND\/ B\u578b\u4f1a\u8bae\uff0c\u5728\u90a3\u91cc\u5b83\u5c06\u83b7\u5f97\u62df\u8bae\u8bd5\u9a8c\u7684\u534f\u8bae\u534f\u52a9\uff0c\u5305\u62ec\u8bd5\u9a8c\u7ec8\u70b9\u7684\u6307\u5bfc\uff0c\u5305\u62ec\u6bcf\u6708\u5934\u75db\u65e5\u548c\u9885\u5185\u538b\u3002 \u6839\u636e\u8be5\u516c\u53f8\u7684\u8bf4\u6cd5\uff0c\u6bcf\u6708\u7684\u5934\u75db\u65e5\u548c\u9885\u5185\u538b\u4e0e\u53bb\u5e74\u5e74\u5e95\u5728Presendin\u5b64\u513f\u836f\u6307\u5b9a\u4e0b\u4eceEuropean Medicines Agency\u5f97\u5230\u7684\u6cbb\u7597\u65b9\u6848\u5efa\u8bae\u4e00\u81f4\u3002 \u4f5c\u4e3aFDA\u4e4b\u524d\u8981\u6c42\u7684\u4e00\u90e8\u5206\uff0cInvex\u4e5f\u5411FDA\u63d0\u4ea4\u4e86\u4e00\u4efd\u5b8c\u6574\u7684\u7814\u7a76\u65b9\u6848\u548c\u7edf\u8ba1\u5206\u6790\u8ba1\u5212\u3002 Invex\u8463\u4e8b\u957fJason Loveridge\u535a\u58eb\u8868\u793a\uff0cFDA\u7684\u7533\u8bf7\u5bf9\u8be5\u516c\u53f8\u6765\u8bf4\u662f\u4e00\u4e2a\u201c\u91cd\u8981\u7684\u91cc\u7a0b\u7891\u201d\u3002 \u201d\u534f\u8bae\u7684\u7814\u7a76\u548c\u7edf\u8ba1\u5206\u6790\u8ba1\u5212\u7684\u5b8c\u6210\u5728\u5927\u7ea6\u4e09\u4e2a\u6708\u7684\u6700\u540e\u83b7\u5f97\u6b27\u6d32\u836f\u54c1\u5c40\u53cd\u9988\u8bc1\u660eInvex\u56e2\u961f\u7684\u627f\u8bfa,\u6211\u4eec\u7684\u4e13\u5bb6\u533b\u7597\/\u79d1\u5b66\u548c\u7ba1\u7406\u987e\u95ee\u548c\u7814\u7a76\u7edf\u8ba1\u5b66\u5bb6\u4e3aPresendin\u7279\u53d1\u6027\u9885\u5185\u9ad8\u8840\u538b\u53d1\u5c55\u9879\u76ee Loveridge\u535a\u58eb\u8865\u5145\u8bf4\uff0cFDA\u7684\u53cd\u9988\u5c06\u662f\u4e00\u4e2a\u201c\u91cd\u8981\u7684\u8003\u8651\u56e0\u7d20\u201d\uff0c\u56e0\u4e3aInvex\u6253\u7b97\u57289\u6708\u4efd\u7684\u5b63\u5ea6\u4f1a\u8bae\u6b63\u5f0f\u8bb0\u5f55\u4e4b\u540e\u63d0\u4ea4IND\u3002 \u201c\u6211\u4eec\u5f88\u9ad8\u5174\u6709\u673a\u4f1a\u4e0eFDA\u5206\u4eab\u6211\u4eec\u7684\u8ba1\u5212\uff0c\u6211\u4eec\u63d0\u8bae\u7684\u4f1a\u8bae\u8981\u6c42\u83b7\u5f97\u6279\u51c6\u3002\u201d Loveridge\u535a\u58eb\u6307\u51fa\uff0c\u62df\u8bae\u7684III\u671f\u8bd5\u9a8c\u5bf9\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u60a3\u8005\u5f88\u91cd\u8981\uff0c\u4ed6\u4eec\u76ee\u524d\u4e0d\u80fd\u4f9d\u8d56\u4efb\u4f55\u5df2\u6279\u51c6\u7684\u6cbb\u7597\u65b9\u6cd5\u6765\u6709\u6548\u5730\u7ba1\u7406\u8fd9\u79cd\u75be\u75c5\uff0c\u5e76\u6539\u5584\u4ed6\u4eec\u7684\u751f\u6d3b\u8d28\u91cf\uff0c\u5982\u51cf\u5c11\u5934\u75db\u3002 \u7279\u53d1\u6027\u9885\u5185\u9ad8\u8840\u538b \u6839\u636eInvex\u7684\u8bf4\u6cd5\uff0c\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u662f\u4e00\u79cd\u4ee5\u201c\u9885\u5185\u538b\u4e25\u91cd\u5347\u9ad8\u201d\u4e3a\u7279\u5f81\u7684\u81f4\u6b8b\u6027\u75be\u75c5\u3002\u8fd9\u4f1a\u5bfc\u81f4\u65e5\u5e38\u5934\u75db\u5e76\u538b\u8feb\u89c6\u795e\u7ecf\u3002 \u53d1\u75c5\u5e74\u9f84\u901a\u5e38\u572820 &#8211; 30\u5c81\u4e4b\u95f4\uff0c\u591a\u89c1\u4e8e\u80a5\u80d6\u5973\u6027\u3002 Invex\u6307\u51fa\uff0c\u8fd9\u79cd\u75be\u75c5\u662f\u4e00\u79cd\u5feb\u901f\u589e\u957f\u7684\u8ff9\u8c61\u2014\u2014\u5728\u8fc7\u53bb\u5341\u5e74\u4e2d\uff0c\u53d1\u75c5\u7387\u589e\u52a0\u4e86350%\u4ee5\u4e0a\u3002 Presendin\u662fInvex\u516c\u53f8\u827e\u585e\u90a3\u80bd\u7684\u54c1\u724c\u540d\u79f0\uff0c\u66fe\u4e8e2005\u5e74\u548c2006\u5e74\u83b7\u5f97\u7f8e\u56fd\u548c\u6b27\u76df\u6279\u51c6\u7528\u4e8e\u6cbb\u75972\u578b\u7cd6\u5c3f\u75c5\u3002 \u7814\u7a76\u8868\u660e\uff0c\u8fd9\u79cd\u836f\u7269\u6700\u7ec8\u53ef\u4ee5\u51cf\u5c11\u5927\u8111\u4e2d\u7684\u8111\u810a\u6db2\u3002\u7136\u800c\uff0c\u76ee\u524d\u7cd6\u5c3f\u75c5\u7684\u5242\u578b\u5e76\u6ca1\u6709\u88ab\u4f18\u5316\u7528\u4e8e\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u3002<\/p>\n","protected":false},"author":3,"featured_media":10095,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[273],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v17.3 (Yoast SEO v21.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Invex Therapeutics\u4e0e\u7f8e\u56fdFDA\u5c31Presendin\u2122\u5728IIH\u60a3\u8005\u4e2d\u7684\u4e34\u5e8a\u8bd5\u9a8c\u8fdb\u884c\u4e86pre-IND\u4f1a\u8c08<\/title>\n<meta name=\"description\" content=\"Invex Therapeutics (ASX: IXC)\u5df2\u5411\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40(fda)\u63d0\u4ea4\u4e86\u4e00\u4efd\u7814\u7a76\u524d\u65b0\u836f\u7533\u8bf7\uff0c\u7528\u4e8eIII\u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u8bc4\u4f30\u5176\u836f\u7269Presendin\u7528\u4e8e\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b(IIH)\u60a3\u8005\u3002\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Invex Therapeutics\u4e0e\u7f8e\u56fdFDA\u5c31Presendin\u2122\u5728IIH\u60a3\u8005\u4e2d\u7684\u4e34\u5e8a\u8bd5\u9a8c\u8fdb\u884c\u4e86pre-IND\u4f1a\u8c08\" \/>\n<meta property=\"og:description\" content=\"Invex Therapeutics (ASX: IXC)\u5df2\u5411\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40(fda)\u63d0\u4ea4\u4e86\u4e00\u4efd\u7814\u7a76\u524d\u65b0\u836f\u7533\u8bf7\uff0c\u7528\u4e8eIII\u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u8bc4\u4f30\u5176\u836f\u7269Presendin\u7528\u4e8e\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b(IIH)\u60a3\u8005\u3002\" \/>\n<meta property=\"og:url\" content=\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-pre-ind-meeting-us-fda-presendin-trial-iih-sufferers\/\" \/>\n<meta property=\"og:site_name\" content=\"smallcapsCN\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-30T23:35:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-29T17:49:01+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/smallcaps-production.test\/wp-content\/uploads\/2021\/03\/Invex-Therapeutics-ASX-IXC-pre-IND-meeting-US-FDA-Presendin-trial-IIH-sufferers.jpg\" \/>\n<meta name=\"author\" content=\"Lorna Nicholas\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Invex Therapeutics\u4e0e\u7f8e\u56fdFDA\u5c31Presendin\u2122\u5728IIH\u60a3\u8005\u4e2d\u7684\u4e34\u5e8a\u8bd5\u9a8c\u8fdb\u884c\u4e86pre-IND\u4f1a\u8c08\" \/>\n<meta name=\"twitter:description\" content=\"Invex Therapeutics (ASX: IXC)\u5df2\u5411\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40(fda)\u63d0\u4ea4\u4e86\u4e00\u4efd\u7814\u7a76\u524d\u65b0\u836f\u7533\u8bf7\uff0c\u7528\u4e8eIII\u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u8bc4\u4f30\u5176\u836f\u7269Presendin\u7528\u4e8e\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b(IIH)\u60a3\u8005\u3002\" \/>\n<meta name=\"twitter:image\" content=\"http:\/\/smallcaps-production.test\/wp-content\/uploads\/2021\/03\/Invex-Therapeutics-ASX-IXC-pre-IND-meeting-US-FDA-Presendin-trial-IIH-sufferers.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Lorna Nicholas\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-pre-ind-meeting-us-fda-presendin-trial-iih-sufferers\/\",\"url\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-pre-ind-meeting-us-fda-presendin-trial-iih-sufferers\/\",\"name\":\"Invex Therapeutics\u4e0e\u7f8e\u56fdFDA\u5c31Presendin\u2122\u5728IIH\u60a3\u8005\u4e2d\u7684\u4e34\u5e8a\u8bd5\u9a8c\u8fdb\u884c\u4e86pre-IND\u4f1a\u8c08\",\"isPartOf\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\"},\"datePublished\":\"2021-03-30T23:35:49+00:00\",\"dateModified\":\"2023-08-29T17:49:01+00:00\",\"author\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/3e816860d3443582b1918467347eeb60\"},\"description\":\"Invex Therapeutics (ASX: IXC)\u5df2\u5411\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40(fda)\u63d0\u4ea4\u4e86\u4e00\u4efd\u7814\u7a76\u524d\u65b0\u836f\u7533\u8bf7\uff0c\u7528\u4e8eIII\u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u8bc4\u4f30\u5176\u836f\u7269Presendin\u7528\u4e8e\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b(IIH)\u60a3\u8005\u3002\",\"breadcrumb\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-pre-ind-meeting-us-fda-presendin-trial-iih-sufferers\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-pre-ind-meeting-us-fda-presendin-trial-iih-sufferers\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-pre-ind-meeting-us-fda-presendin-trial-iih-sufferers\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/smallcapscn.x5view.co\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Invex Therapeutics\u4e0e\u7f8e\u56fdFDA\u5c31Presendin&#x2122;\u5728IIH\u60a3\u8005\u4e2d\u7684\u4e34\u5e8a\u8bd5\u9a8c\u8fdb\u884c\u4e86pre-IND\u4f1a\u8c08\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\",\"url\":\"https:\/\/smallcapscn.x5view.co\/\",\"name\":\"smallcapsCN\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/3e816860d3443582b1918467347eeb60\",\"name\":\"Lorna Nicholas\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/431dd83ad861252293034fed39d5d7a5?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/431dd83ad861252293034fed39d5d7a5?s=96&d=mm&r=g\",\"caption\":\"Lorna Nicholas\"},\"description\":\"Lorna has more than 15 years' experience as a business\/finance journalist and editor. She has written for numerous industry publications reporting on various sectors, including: resources, energy, construction, biotech, pharma, science and technology, agriculture, and chemicals. Specialising in resources, Lorna has also covered a myriad of small and large cap ASX and dual-listed stocks.\",\"url\":\"https:\/\/smallcapscn.x5view.co\/?author=3\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Invex Therapeutics\u4e0e\u7f8e\u56fdFDA\u5c31Presendin\u2122\u5728IIH\u60a3\u8005\u4e2d\u7684\u4e34\u5e8a\u8bd5\u9a8c\u8fdb\u884c\u4e86pre-IND\u4f1a\u8c08","description":"Invex Therapeutics (ASX: IXC)\u5df2\u5411\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40(fda)\u63d0\u4ea4\u4e86\u4e00\u4efd\u7814\u7a76\u524d\u65b0\u836f\u7533\u8bf7\uff0c\u7528\u4e8eIII\u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u8bc4\u4f30\u5176\u836f\u7269Presendin\u7528\u4e8e\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b(IIH)\u60a3\u8005\u3002","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Invex Therapeutics\u4e0e\u7f8e\u56fdFDA\u5c31Presendin\u2122\u5728IIH\u60a3\u8005\u4e2d\u7684\u4e34\u5e8a\u8bd5\u9a8c\u8fdb\u884c\u4e86pre-IND\u4f1a\u8c08","og_description":"Invex Therapeutics (ASX: IXC)\u5df2\u5411\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40(fda)\u63d0\u4ea4\u4e86\u4e00\u4efd\u7814\u7a76\u524d\u65b0\u836f\u7533\u8bf7\uff0c\u7528\u4e8eIII\u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u8bc4\u4f30\u5176\u836f\u7269Presendin\u7528\u4e8e\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b(IIH)\u60a3\u8005\u3002","og_url":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-pre-ind-meeting-us-fda-presendin-trial-iih-sufferers\/","og_site_name":"smallcapsCN","article_published_time":"2021-03-30T23:35:49+00:00","article_modified_time":"2023-08-29T17:49:01+00:00","og_image":[{"url":"http:\/\/smallcaps-production.test\/wp-content\/uploads\/2021\/03\/Invex-Therapeutics-ASX-IXC-pre-IND-meeting-US-FDA-Presendin-trial-IIH-sufferers.jpg"}],"author":"Lorna Nicholas","twitter_card":"summary_large_image","twitter_title":"Invex Therapeutics\u4e0e\u7f8e\u56fdFDA\u5c31Presendin\u2122\u5728IIH\u60a3\u8005\u4e2d\u7684\u4e34\u5e8a\u8bd5\u9a8c\u8fdb\u884c\u4e86pre-IND\u4f1a\u8c08","twitter_description":"Invex Therapeutics (ASX: IXC)\u5df2\u5411\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40(fda)\u63d0\u4ea4\u4e86\u4e00\u4efd\u7814\u7a76\u524d\u65b0\u836f\u7533\u8bf7\uff0c\u7528\u4e8eIII\u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u8bc4\u4f30\u5176\u836f\u7269Presendin\u7528\u4e8e\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b(IIH)\u60a3\u8005\u3002","twitter_image":"http:\/\/smallcaps-production.test\/wp-content\/uploads\/2021\/03\/Invex-Therapeutics-ASX-IXC-pre-IND-meeting-US-FDA-Presendin-trial-IIH-sufferers.jpg","twitter_misc":{"Written by":"Lorna Nicholas"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-pre-ind-meeting-us-fda-presendin-trial-iih-sufferers\/","url":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-pre-ind-meeting-us-fda-presendin-trial-iih-sufferers\/","name":"Invex Therapeutics\u4e0e\u7f8e\u56fdFDA\u5c31Presendin\u2122\u5728IIH\u60a3\u8005\u4e2d\u7684\u4e34\u5e8a\u8bd5\u9a8c\u8fdb\u884c\u4e86pre-IND\u4f1a\u8c08","isPartOf":{"@id":"https:\/\/smallcapscn.x5view.co\/#website"},"datePublished":"2021-03-30T23:35:49+00:00","dateModified":"2023-08-29T17:49:01+00:00","author":{"@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/3e816860d3443582b1918467347eeb60"},"description":"Invex Therapeutics (ASX: IXC)\u5df2\u5411\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40(fda)\u63d0\u4ea4\u4e86\u4e00\u4efd\u7814\u7a76\u524d\u65b0\u836f\u7533\u8bf7\uff0c\u7528\u4e8eIII\u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u8bc4\u4f30\u5176\u836f\u7269Presendin\u7528\u4e8e\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b(IIH)\u60a3\u8005\u3002","breadcrumb":{"@id":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-pre-ind-meeting-us-fda-presendin-trial-iih-sufferers\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/smallcapscn.x5view.co\/invex-therapeutics-pre-ind-meeting-us-fda-presendin-trial-iih-sufferers\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-pre-ind-meeting-us-fda-presendin-trial-iih-sufferers\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/smallcapscn.x5view.co\/"},{"@type":"ListItem","position":2,"name":"Invex Therapeutics\u4e0e\u7f8e\u56fdFDA\u5c31Presendin&#x2122;\u5728IIH\u60a3\u8005\u4e2d\u7684\u4e34\u5e8a\u8bd5\u9a8c\u8fdb\u884c\u4e86pre-IND\u4f1a\u8c08"}]},{"@type":"WebSite","@id":"https:\/\/smallcapscn.x5view.co\/#website","url":"https:\/\/smallcapscn.x5view.co\/","name":"smallcapsCN","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/3e816860d3443582b1918467347eeb60","name":"Lorna Nicholas","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/431dd83ad861252293034fed39d5d7a5?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/431dd83ad861252293034fed39d5d7a5?s=96&d=mm&r=g","caption":"Lorna Nicholas"},"description":"Lorna has more than 15 years' experience as a business\/finance journalist and editor. She has written for numerous industry publications reporting on various sectors, including: resources, energy, construction, biotech, pharma, science and technology, agriculture, and chemicals. Specialising in resources, Lorna has also covered a myriad of small and large cap ASX and dual-listed stocks.","url":"https:\/\/smallcapscn.x5view.co\/?author=3"}]}},"_links":{"self":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/2895"}],"collection":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2895"}],"version-history":[{"count":1,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/2895\/revisions"}],"predecessor-version":[{"id":11282,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/2895\/revisions\/11282"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/media\/10095"}],"wp:attachment":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2895"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2895"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2895"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}